AU2002218311A1 - Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease - Google Patents

Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease

Info

Publication number
AU2002218311A1
AU2002218311A1 AU2002218311A AU1831102A AU2002218311A1 AU 2002218311 A1 AU2002218311 A1 AU 2002218311A1 AU 2002218311 A AU2002218311 A AU 2002218311A AU 1831102 A AU1831102 A AU 1831102A AU 2002218311 A1 AU2002218311 A1 AU 2002218311A1
Authority
AU
Australia
Prior art keywords
treatment
inflammatory bowel
bowel disease
protein transferase
transferase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002218311A
Inventor
Charles Ronald Bowden
David William End
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2002218311A1 publication Critical patent/AU2002218311A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to the use of certain farnesyl protein transferase inhibitors for the manufacture of a medicament for the treatment of inflammatory bowel disease.
AU2002218311A 2000-11-28 2001-11-20 Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease Abandoned AU2002218311A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25334600P 2000-11-28 2000-11-28
US60253346 2000-11-28
PCT/EP2001/013540 WO2002043733A1 (en) 2000-11-28 2001-11-20 Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease

Publications (1)

Publication Number Publication Date
AU2002218311A1 true AU2002218311A1 (en) 2002-06-11

Family

ID=22959893

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002218311A Abandoned AU2002218311A1 (en) 2000-11-28 2001-11-20 Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease

Country Status (11)

Country Link
US (1) US20040044032A1 (en)
EP (1) EP1339407B1 (en)
JP (1) JP4231691B2 (en)
AT (1) ATE323490T1 (en)
AU (1) AU2002218311A1 (en)
CY (1) CY1106122T1 (en)
DE (1) DE60118953T2 (en)
DK (1) DK1339407T3 (en)
ES (1) ES2261523T3 (en)
PT (1) PT1339407E (en)
WO (1) WO2002043733A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
JP2007529555A (en) * 2004-03-18 2007-10-25 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド How to treat synucleinopathy
EP1744751A4 (en) * 2004-03-18 2010-03-10 Brigham & Womens Hospital Methods for the treatment of synucleinopathies
WO2005089504A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
SI2362218T1 (en) 2004-11-05 2014-12-31 Janssen Pharmaceutica N.V. Methods of monitoring the efficacy of farnesyltransferase inhibitors
WO2007075923A2 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
MX2011005096A (en) * 2008-11-13 2011-11-18 Link Medicine Corp Azaquinolinone derivatives and uses thereof.
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
ES2628365T3 (en) 2012-10-16 2017-08-02 Janssen Pharmaceutica N.V. Phenyl-linked quinolinyl modulators of ROR-GAMA-T
AU2013331493A1 (en) 2012-10-16 2015-04-09 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORyt
PL2909192T3 (en) 2012-10-16 2017-09-29 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
BR112016008258A2 (en) 2013-10-15 2017-10-10 Janssen Pharmaceutica Nv quinolinyl ror? t modulators
AU2014334619A1 (en) 2013-10-15 2016-04-21 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORyt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
CN108371711A (en) 2015-08-17 2018-08-07 库拉肿瘤学公司 Use the method for farnesyl transferase inhibitor treating cancer patient
SG11201903786UA (en) 2016-11-03 2019-05-30 Kura Oncology Inc Farnesyltransferase inhibitors for use in methods of treating cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0664128A4 (en) * 1992-10-07 1997-12-17 Sumitomo Pharma Pharmaceutical composition for inhibiting tumor necrosis factor production.
US5470832A (en) * 1994-01-31 1995-11-28 Merck & Co., Inc. Inhibitors of geranylgeranyl-protein transferase
US5574025A (en) * 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
TW316902B (en) * 1994-12-28 1997-10-01 Janssen Pharmaceutica Nv
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
IL123568A (en) * 1995-12-08 2001-08-08 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibiting (imidazole-5-yl) methyl-2-quinolinone derivatives, their preparation, pharmaceutical compositions containing them and their preparation, and medicaments comprising them
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US5929077A (en) * 1996-11-08 1999-07-27 Leftheris; Katerina Thioproline-containing inhibitors of farnesyl protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
GB2323783A (en) * 1997-04-02 1998-10-07 Ferring Bv Group Holdings Inhibitors of farnesyl protein transferase
HUP0001122A3 (en) * 1997-04-25 2002-03-28 Janssen Pharmaceutica Nv Farnesyltransferase inhibiting quinazolinones
TW527355B (en) * 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
SK286072B6 (en) * 1998-12-23 2008-02-05 Janssen Pharmaceutica N. V. 1,2-Annelated quinoline derivatives, method for their preparation, intermediates, pharmaceutical composition and their use

Also Published As

Publication number Publication date
EP1339407B1 (en) 2006-04-19
DE60118953T2 (en) 2007-01-11
PT1339407E (en) 2006-08-31
CY1106122T1 (en) 2011-06-08
ATE323490T1 (en) 2006-05-15
EP1339407A1 (en) 2003-09-03
JP2004514695A (en) 2004-05-20
US20040044032A1 (en) 2004-03-04
JP4231691B2 (en) 2009-03-04
DK1339407T3 (en) 2006-08-14
DE60118953D1 (en) 2006-05-24
WO2002043733A1 (en) 2002-06-06
ES2261523T3 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
AU2002218311A1 (en) Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
AU2001233726A1 (en) Farnesyl protein transferase inhibitors for treating breast cancer
BR0115411A (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases.
MY127290A (en) New use of flibanserin
WO2003042246A3 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
MXPA03002814A (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases.
HN2001000244A (en) SPIROPIRIMIDIN INHIBITORS - 2, 4, 6 - TRIONA METALOPROTEINASAS.
GB0112348D0 (en) Compounds
IN2005KO00312A (en)
TNSN06138A1 (en) INHIBITORS OF THE MUTANT FORM OF KIT
BR0211972A (en) Ophthalmic Composition
AU2002363182A1 (en) Smad7 inhibitors for the treatment of cns diseases
GB0002336D0 (en) Medicaments
AU2000265525A1 (en) Medicament for treating intestinal diseases
NO20014241D0 (en) C16-unsaturated FP-selective prostaglandin analogs
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
MXPA04005809A (en) Protein kinase inhibitors.
GB9907571D0 (en) Compounds
SE0004827D0 (en) Therapeutic compounds
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
NO20032411L (en) Use of substituted 6-dimethylaminomethyl-1-phenylcyclohexane compounds for the treatment of urinary incontinence
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
AU3071999A (en) Use of pkc inhibitors for the manufacture of a medicament for the treatment of autoimmune diseases
TW200509945A (en) Agent for treatment of anal disease
PL359727A1 (en) Crystalline pharmaceutical